Barclays’s CalciMedica CALC Stock Holding History

Barclays’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57	Closed	-$175	–	5281
2025 Q3	$175	Buy	+57	New	+$164	﹤0.01%	5247

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

MPM

Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

Barclays's CALC Position: Q4 2025 in Review

Barclays sold out of CalciMedica (CALC) in Q4 2025, closing a stake of 57 shares — an estimated $175 sold.

Barclays first reported a position in CALC in Q3 2025 and held it in 1 quarter. The position peaked at $175 in Q3 2025. 30 funds tracked by Wall St. Rank hold CALC as of Q4 2025.

Barclays reported no remaining CalciMedica position as of Q4 2025 after selling out during the quarter.
Barclays sold 57 CalciMedica shares in Q4 2025, an estimated $175.
Barclays first reported a position in CalciMedica in Q3 2025 and held it in 1 quarter.
Barclays's CalciMedica position peaked at $175 in Q3 2025.
30 funds tracked by Wall St. Rank held CalciMedica as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.